Controlled Substance Scheduling Amendments
SB 83 amends Utah's controlled substance scheduling laws to automatically align state schedules with federal changes. Specifically, it requires Utah to automatically reschedule pharmaceutical compositions of substances previously classified as Schedule I under federal law if the federal government reschedules them. This affects pharmaceutical companies and healthcare providers who handle these substances, as it eliminates the need for separate state legislative action when federal scheduling changes. The bill does not add new substances to schedules or appropriate funds, focusing solely on streamlining the rescheduling process.
Bill status
signed
all 5 stages cleared
Introduction
Jan 2026
Committee Review
Feb 2026
Senate Passage
Feb 2026
House Passage
Feb 2026
Signed into Law
Mar 2026
Introduced Jan 20, 2026
Signed Mar 24, 2026
Maddy AI version diff · 3 comparisons
What changed between versions
Amended Excerpts 2/25/2026 11:02:537
→
Amended 2/25/2026 11:02:537
·
3 edits
MINOR
This bill updates Utah's list of controlled substances in Schedule I to include numerous synthetic opioids and related compounds, such as various fentanyl analogs and Phenibut. It also clarifies that any pharmaceutical composition approved by the FDA is automatically scheduled in Utah if the federal government schedules it, ensuring state laws align with federal changes. The changes expand the state's ability to regulate a wider range of potentially dangerous drugs.
Scope change
The bill expands the scope of Schedule I controlled substances in Utah to include many new synthetic opioids and specific pharmaceutical compositions that are federally regulated.
SCOPE
Added a comprehensive list of specific Schedule I substances, including numerous fentanyl analogs (e.g., Acetyl fentanyl, Para-fluorofentanyl) and other drugs like Phenibut and Etizolam.
ELIGIBILITY
Established a rule that any FDA-approved pharmaceutical composition is automatically scheduled in Utah if the federal government schedules it, removing the need for separate state action for each new drug.
DEFINITION
Clarified the definition of 'pharmaceutical composition' to specifically mean drugs with FDA approval following clinical trials.
Floor votes · Senate Feb 10, 2026 · House Feb 25, 2026
How they voted
27–0
Passed · 2 other
Total votes 29
Feb 10, 2026
D
Democratic6
100% Yea
N
Forward1
100% Yea
R
Republican22
90% Yea
Vote distribution
All Yea
All Nay
Mixed
No data
Full legislative history
Actions timeline
Total actions
44
Key actions
10
Committee
6
Amendments
2
Mar 24, 2026
Signed into law
Governor Signed
executive
Feb 27, 2026
Upper · Passed
Senate/ signed by President/ sent for enrolling
upper
Feb 26, 2026
Upper · Passed
House/ signed by Speaker/ returned to Senate
upper
Feb 26, 2026
Lower · Passed
Senate/ concurs with House amendment
lower
Feb 25, 2026
Upper · Passed
House/ passed 3rd reading
upper
Feb 25, 2026
Introduced
House/ floor amendment
lower
Feb 19, 2026
Lower · Passed
House/ committee report favorable [House Health and Human Services Committee]
lower
Feb 19, 2026
Lower · Passed
House Comm - Favorable Recommendation [House Health and Human Services Committee]
lower
Feb 12, 2026
Committee
House/ to standing committee [House Health and Human Services Committee]
lower
Feb 10, 2026
Introduced
House/ 1st reading (Introduced)
lower
Feb 10, 2026
Lower · Passed
Senate/ passed 3rd reading
lower
Jan 27, 2026
Upper · Passed
Senate/ committee report favorable [Senate Health and Human Services Committee]
upper
Jan 26, 2026
Upper · Passed
Senate Comm - Favorable Recommendation [Senate Health and Human Services Committee]
upper
Jan 20, 2026
Committee
Senate/ to standing committee [Senate Health and Human Services Committee]
upper
Jan 20, 2026
Introduced
Senate/ 1st reading (Introduced)
upper
1 primary · 1 co-sponsor
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about SB 83
Scope: UT
Hi! I can help you understand SB 83. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline